ArticleInternal medicine (Tokyo, Japan)2026

Risks and Benefits of Obinutuzumab-based Chemotherapy in the Context of SARS-CoV-2 Infection.

Kohei Shiroshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.